NCT06245486View on ClinicalTrials.gov

Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 10, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Human Papillomavirus Infection
Interventions
DIETARY_SUPPLEMENT

Crispact®

Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247

DIETARY_SUPPLEMENT

Placebo

Placebo

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06245486 - Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses | Biotech Hunter | Biotech Hunter